1 week Ago By ABMN Staff
Raymond James Financial Inc. acquired a new position in CareDx, Inc ( NASDAQ:CDNA – Free Report ) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 172,559 shares of the company’s stock, valued at approximately $3,694,000.
Raymond James Financial Inc. owned approximately 0.32% of CareDx as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Plato Investment Management Ltd grew its holdings in CareDx by 34.1% during the 4th quarter.
Plato Investment Management Ltd now owns 5,390 shares of the company’s stock valued at $116,000 after purchasing an additional 1,370 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in CareDx by 41.5% during the 4th quarter.
IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company’s stock valued at $200,000 after purchasing an additional 2,742 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in CareDx during the 4th quarter valued at $208,000. Cornercap Investment Counsel Inc.
acquired a new stake in CareDx during the 4th quarter valued at $214,000. Finally, Inceptionr LLC acquired a new position in CareDx during the 4th quarter worth $240,000. Analyst Ratings Changes CDNA has been the topic of several research reports.
StockNews.com upgraded CareDx from a “hold” rating to a “buy” rating in a research note on Wednesday, February 26th. HC Wainwright cut their price objective on CareDx from $26.
00 to $25.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Stephens restated an “overweight” rating and set a $40.
00 price objective on shares of CareDx in a research note on Thursday, February 27th. The Goldman Sachs Group cut their price objective on CareDx from $34.00 to $26.
00 and set a “buy” rating on the stock in a research note on Thursday, April 17th. Finally, Wells Fargo & Company upgraded CareDx from an “underweight” rating to an “equal weight” rating and dropped their price target for the stock from $28.00 to $24.
00 in a research report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.
com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $30.33. CareDx Trading Down 0.
1 % NASDAQ:CDNA opened at $18.48 on Monday. CareDx, Inc has a 1-year low of $7.
61 and a 1-year high of $34.84. The firm has a market capitalization of $1.
02 billion, a price-to-earnings ratio of -6.84 and a beta of 2.18.
The business’s fifty day moving average price is $19.07 and its 200 day moving average price is $21.81.
CareDx ( NASDAQ:CDNA – Get Free Report ) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, topping the consensus estimate of $0.
05 by $1.46. The business had revenue of $86.
58 million during the quarter, compared to analysts’ expectations of $84.56 million. CareDx had a negative net margin of 45.
90% and a negative return on equity of 53.70%. Equities analysts forecast that CareDx, Inc will post -0.
9 earnings per share for the current year. CareDx Profile ( Free Report ) CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Featured Articles Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter ..
